GlassScriptPhysician profile
Barbara A Berry
NPI 1457411613
$4,367.93
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2020: $702 · 2021: $2,032 · 2022: $1,063.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,527.14 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $453.55 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $351.16 | 2019-2022 | |
| Abbott Laboratories | $331.30 | 2021-2022 | |
| Amgen INC. | $284.70 | 2019-2022 | |
| Abbvie INC. | $185.11 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.65 | 2019-2022 | |
| Boston Scientific Corporation | $113.44 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $105.07 | 2019-2021 | |
| Astellas Pharma US INC | $93.78 | 2019-2021 | |
| Lilly USA, LLC | $84.30 | 2019-2021 | |
| Pfizer INC. | $78.82 | 2019-2022 | |
| Glaxosmithkline, LLC. | $68.68 | 2022 | |
| Novo Nordisk INC | $64.61 | 2019-2022 | |
| Amarin Pharma, INC. | $62.38 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $55.32 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $52.25 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $48.65 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.89 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.58 | 2019-2021 | |
| Eisai INC. | $37.01 | 2020 | |
| Allergan, INC. | $28.88 | 2020 | |
| Almatica Pharma LLC | $24.46 | 2022 | |
| Opko Pharmaceuticals, LLC | $20.79 | 2022 | |
| Valeritas, INC. | $19.78 | 2019 | |
| Sanofi Pasteur INC. | $18.86 | 2019 | |
| Hikma Pharmaceuticals USA | $13.67 | 2020 | |
| Medtronic, INC. | $13.50 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.60 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.